secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001193125-24-255185
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

ARS Pharma licenses neffy to ALK for $145M upfront; up to $320M milestones
--------------------------------------------------------------------------

- Upfront $145M from ALK; regulatory/commercial milestones up to $20M and sales milestones up to $300M.
- Exclusive license for epinephrine nasal spray (neffy) outside US, Japan, China, Australia, New Zealand for all human uses.
- Tiered royalties in mid-to-high teens on net sales; ARS supplies product for first 5 years under supply agreement.
- ALK must use commercially reasonable efforts for regulatory approval and commercialization; ARS may terminate if ALK sells competing non-injectable epinephrine in US.
- Deal covers anaphylaxis and Type I allergic reactions; parties may agree on future indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000119312524255185/0001193125-24-255185-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000119312524255185/d810986d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-255185

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer